Integrated Filling (Finance)
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Evoq Remedies Limited, a small agro-commodity trading firm, reported H1 FY26 results showing revenue from operations more than doubling to Rs 2,550.68 lakhs from Rs 1,175.67 lakhs in H1 FY25 (up ~117%). Total revenue stood at Rs 2,656.82 lakhs, and the company swung to a marginal profit of Rs 5.43 lakhs from a loss of Rs 162.44 lakhs a year ago. However, the auditor's review report includes a detailed Annexure 1 flagging serious concerns: an ongoing SEBI investigation and a show cause notice over use of Rs 9.21 crore from a preferential allotment, non-compliance with mandatory audit trail software rules, unconfirmed supplier advances of Rs 1,250.87 lakhs, a pending GST demand of Rs 655.03 lakhs from FY18, a disputed income tax demand of Rs 39.99 lakhs, related-party loans of Rs 668.86 lakhs with non-compliance of multiple Companies Act sections, and unpaid TDS/TCS of Rs 38.23 lakhs. Cash and equivalents remain thin at Rs 30.78 lakhs against short-term borrowings of Rs 3,265.50 lakhs.
Despite the strong revenue rebound, the auditor's multiple qualifications, ongoing SEBI probe into the preferential allotment funds, and sizeable tax/GST litigations create significant regulatory and governance overhang. Retail investors should treat the headline turnaround with caution, as the profitability is razor-thin and contingent liabilities could materially impact the small balance sheet.